Search

PW2101

The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals. … PW2101 is a beta blocker intended for the treatment of hypertension and angina.

Nifedipine

[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. … [A190273] The most popular of the third generation dihydropyridines is [amlodipine].[A190273] Nifedipine was granted FDA approval on 31 December 1981.[L11383]

Sodium phosphate, monobasic, unspecified form

ANA971

ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself. … ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

Iopentol

Iopentol is used as a contrast medium.

XL228

XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

GTI 2040

GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

FX06

FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

Cypermethrin

Cyfluthrin